As the U.S. Food and Drug Administration’s (FDA) May 22 deadline for compounding pharmacies to cease selling their versions of semaglutide takes effect, Novo Nordisk is launching a multifaceted strategy to capture more of the obesity drug market. The company announced a special pricing initiative for self-paying, first-time users of Wegovy, offering a one-month supply for $199 through June 30. Quoting the company, "After that, the drug will go for its standing price of $499 a month for cash-paying customers, which was discounted in March from a previous price tag of $650 per month."
This pricing move is intended to help former users of compounded semaglutide transition to the FDA-approved version. Dave Moore, executive vice president of Novo’s U.S. operations, emphasized, “We are doubling down on our commitment to accessibility, availability, and affordability of authentic, FDA-approved Wegovy.”
In conjunction with the pricing offer, Novo Nordisk has introduced a new marketing initiative titled “Choose the Real Thing.” This campaign follows the earlier “Check Before You Inject” series, reinforcing the risks associated with counterfeit versions of semaglutide and directing viewers to educational content on a Novo-hosted webpage. The new digital ads will begin airing at the end of May.
The Danish pharmaceutical giant has been actively countering unauthorized semaglutide products through both legal and strategic measures. "The company has also filed nearly 120 lawsuits targeting compounding pharmacies across 34 states and will continue pursuing legal action,” Novo stated in its Thursday announcement.
Previously, compounding pharmacies were allowed to produce semaglutide alternatives during the FDA-declared shortage. However, that designation was lifted in February, prompting regulatory action. As Novo clarified, “Any entity that mass produces or sells knockoff 'semaglutide' is breaking the law and putting patient safety at risk.”
To further extend its reach, Novo Nordisk has partnered with telehealth platforms that had formerly distributed compounded semaglutide. These include Hims & Hers, Ro, and LifeMD, which now offer the branded version of Wegovy via Novo’s direct-to-consumer platform, NovoCare.
Despite the winding down of compounded competition, Novo is still feeling the impact on its bottom line. The company recently revised its annual sales forecast downward, citing “lower-than-planned penetration of branded GLP-1 treatments in the U.S., impacted by compounded GLP-1s,” according to a first-quarter financial update.
Additionally, Novo is facing intensified rivalry from Eli Lilly in the obesity treatment sector. The increasing competition and market dynamics were linked to the recent resignation of CEO Lars Fruergaard J?rgensen, as the company begins the search for his replacement.
